Targeting ATF5 in Cancer

James M Angelastro

doi:10.1016/j.trecan.2017.05.004

Targeting ATF5 in Cancer

James M Angelastro

Molecular Biosciences

Research output: Contribution to journal › Short survey

11 Scopus citations

Abstract

The expression of activating transcription factor 5 (ATF5) correlates negatively with patient survival in different types of cancer. ATF5 is important for the survival and proliferation of cancer cells, and can be targeted to selectively trigger cancer cell apoptosis while sparing normal cells. Cell-penetrating peptides combined with a dominant negative ATF5 cargo have recently shown efficacy against brain, breast, melanoma, and prostate cancers.

Original language	English (US)
Pages (from-to)	471-474
Number of pages	4
Journal	Trends in Cancer
Volume	3
Issue number	7
DOIs	https://doi.org/10.1016/j.trecan.2017.05.004
State	Published - Jul 1 2017

Keywords

apoptosis
ATF5
cancer
cell-penetrating peptide
CP-d/n-ATF5
dominant negative

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1016/j.trecan.2017.05.004

Fingerprint Dive into the research topics of 'Targeting ATF5 in Cancer'. Together they form a unique fingerprint.

Cite this

Angelastro, J. M. (2017). Targeting ATF5 in Cancer. Trends in Cancer, 3(7), 471-474. https://doi.org/10.1016/j.trecan.2017.05.004

@article{39c89a68eef9475bb7eb3ad25d61be93,

title = "Targeting ATF5 in Cancer",

abstract = "The expression of activating transcription factor 5 (ATF5) correlates negatively with patient survival in different types of cancer. ATF5 is important for the survival and proliferation of cancer cells, and can be targeted to selectively trigger cancer cell apoptosis while sparing normal cells. Cell-penetrating peptides combined with a dominant negative ATF5 cargo have recently shown efficacy against brain, breast, melanoma, and prostate cancers.",

keywords = "apoptosis, ATF5, cancer, cell-penetrating peptide, CP-d/n-ATF5, dominant negative",

author = "Angelastro, {James M}",

year = "2017",

month = jul,

day = "1",

doi = "10.1016/j.trecan.2017.05.004",

language = "English (US)",

volume = "3",

pages = "471--474",

journal = "Trends in Cancer",

issn = "2405-8033",

publisher = "Cell Press",

number = "7",

}

TY - JOUR

T1 - Targeting ATF5 in Cancer

AU - Angelastro, James M

PY - 2017/7/1

Y1 - 2017/7/1

N2 - The expression of activating transcription factor 5 (ATF5) correlates negatively with patient survival in different types of cancer. ATF5 is important for the survival and proliferation of cancer cells, and can be targeted to selectively trigger cancer cell apoptosis while sparing normal cells. Cell-penetrating peptides combined with a dominant negative ATF5 cargo have recently shown efficacy against brain, breast, melanoma, and prostate cancers.

AB - The expression of activating transcription factor 5 (ATF5) correlates negatively with patient survival in different types of cancer. ATF5 is important for the survival and proliferation of cancer cells, and can be targeted to selectively trigger cancer cell apoptosis while sparing normal cells. Cell-penetrating peptides combined with a dominant negative ATF5 cargo have recently shown efficacy against brain, breast, melanoma, and prostate cancers.

KW - apoptosis

KW - ATF5

KW - cancer

KW - cell-penetrating peptide

KW - CP-d/n-ATF5

KW - dominant negative

UR - http://www.scopus.com/inward/record.url?scp=85020650535&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020650535&partnerID=8YFLogxK

U2 - 10.1016/j.trecan.2017.05.004

DO - 10.1016/j.trecan.2017.05.004

M3 - Short survey

C2 - 28718401

AN - SCOPUS:85020650535

VL - 3

SP - 471

EP - 474

JO - Trends in Cancer

JF - Trends in Cancer

SN - 2405-8033

IS - 7

ER -